Infectious Adverse Events in Patients with Atopic Dermatitis Treated with Baricitinib

References

• Ständer S . Atopic dermatitis. N. Engl. J. Med.384(12), 1136–1143 (2021).
   PubMed Web of Science ®Google Scholar
• Ali F , VyasJ , FinlayAY. Counting the burden: atopic dermatitis and health-related quality of life. Acta Derm. Venereol.100(12), adv00161 (2020).
   PubMed Web of Science ®Google Scholar
• Puar N , ChovatiyaR , PallerAS. New treatments in atopic dermatitis. Ann. Allergy Asthma Immunol.126(1), 21–31 (2021).
   PubMed Web of Science ®Google Scholar
• Abduelmula A , RankinBD , MuftiAet al. Tralokinumab for moderate-to-severe atopic dermatitis in adults. Skin Ther. Lett.28(1), 1–6 (2023).
   PubMedGoogle Scholar
• Wollenberg A , KinbergerM , ArentsBet al. European guideline (EuroGuiDerm) on atopic eczema: part I – systemic therapy. J. Eur. Acad. Dermatol. Venereol.36(9), 1409–1431 (2022).
   PubMed Web of Science ®Google Scholar
• AbbVie . USFDA Approves RINVOQ® (Upadacitinib) to treat adults and children 12years and older with refractory, moderate to severe atopic dermatitis. https://news.abbvie.com/news/press-releases/us-fda-approves-rinvoq-upadacitinib-to-treat-adults-and-children-12-years-and-older-with-refractory-moderate-to-severe-atopic-dermatitis.htm
   Google Scholar
• Chovatiya R , PallerAS. JAK inhibitors in the treatment of atopic dermatitis. J. Allergy Clin. Immunol.148(4), 927–940 (2021).
   PubMed Web of Science ®Google Scholar
• Bieber T , FeistE , IrvineADet al. A review of safety outcomes from clinical trials of baricitinib in rheumatology, dermatology and COVID-19. Adv. Ther.39(11), 4910–4960 (2022).
   PubMed Web of Science ®Google Scholar
• Oliveira C , TorresT. More than skin deep: the systemic nature of atopic dermatitis. Eur. J. Dermatol.29(3), 250–258 (2019).
   PubMed Web of Science ®Google Scholar
• Novak N , CabanillasB. Herpesvirus, serious and opportunistic infections associated with atopic dermatitis. Br. J. Dermatol.186(4), 604–605 (2022).
   PubMed Web of Science ®Google Scholar
• Paller A , JaworskiJC , SimpsonEL , Boguniewiczet al. Major comorbidities of atopic dermatitis: beyond allergic disorders. Am. J. Clin. Dermatol.19(6), 821–838 (2018).
   PubMed Web of Science ®Google Scholar
• Fenner J , SilverbergNB. Skin diseases associated with atopic dermatitis. Clin. Dermatol.36(5), 631–640 (2018).
   PubMed Web of Science ®Google Scholar
• Zhang J , QiF , DongJet al. Application of baricitinib in dermatology. J. Inflamm. Res.15, 1935–1941 (2022).
   PubMed Web of Science ®Google Scholar
• Tanaka Y , LuoY , O’SheaJJet al. Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach. Nat. Rev. Rheumatol.18(3), 133–145 (2022).
   PubMed Web of Science ®Google Scholar
• Garufi C , MacleanM , GadinaM , SpinelliFR. Affecting the effectors: JAK inhibitors modulation of immune cell numbers and functions in patients with rheumatoid arthritis. Expert Rev. Clin. Immunol.18(3), 309–319 (2022).
   PubMed Web of Science ®Google Scholar
• Sanchez GAM , ReinhardtA , RamseySet al. JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies. J. Clin. Invest.128(7), 3041–3052 (2018).
   PubMed Web of Science ®Google Scholar
• Assadiasl S , FatahiY , MosharmovahedB , MohebbiB , NicknamMH. Baricitinib: from rheumatoid arthritis to COVID-19. J. Clin. Pharmacol.61(10), 1274–1285 (2021).
   PubMed Web of Science ®Google Scholar
• Adas MA , AlveynE , CookE , DeyM , GallowayJB , BechmanK. The infection risks of JAK inhibition. Expert Rev. Clin. Immunol.18(3), 253–261 (2022).
   PubMed Web of Science ®Google Scholar
• Hoy SM . Baricitinib: a review in moderate to severe atopic dermatitis. Am. J. Clin. Dermatol.23(3), 409–420 [ Erratum in: Am. J. Clin. Dermatol. 23(5), 747 (2022)].
   PubMed Web of Science ®Google Scholar
• Guttman-Yassky E , SilverbergJI , NemotoOet al. Baricitinib in adult patients with moderate-to-severe atopic dermatitis: a phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study. J. Am. Acad. Dermatol.80(4), 913–921 (2019).
   PubMed Web of Science ®Google Scholar
• Reich K , DeLozierAM , NunesFPet al. Baricitinib improves symptoms in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: patient-reported outcomes from two randomized monotherapy phase III trials. J. Dermatolog. Treat.33(3), 1521–1530 (2022).
   PubMed Web of Science ®Google Scholar
• Simpson EL , FormanS , SilverbergJIet al. Baricitinib in patients with moderate-to-severe atopic dermatitis: results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5). J. Am. Acad. Dermatol.85(1), 62–70 (2021).
   PubMed Web of Science ®Google Scholar
• Reich K , KabashimaK , PerisKet al. Efficacy and safety of baricitinib combined with topical corticosteroids for treatment of moderate to severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol.156(12), 1333–1343 (2020).
   PubMed Web of Science ®Google Scholar
• Wollenberg A , NakaharaT , MaariCet al. Impact of baricitinib in combination with topical steroids on atopic dermatitis symptoms, quality of life and functioning in adult patients with moderate-to-severe atopic dermatitis from the BREEZE-AD7 Phase 3 randomized trial. J. Eur. Acad. Dermatol. Venereol35(7), 1543–1552 (2021).
   PubMed Web of Science ®Google Scholar
• Silverberg JI , SimpsonEL , ThyssenJPet al. Long-term efficacy (up to 68 weeks) of Baricitinib in combination with topical corticosteroids in adult patients with moderate-to-severe atopic dermatitis: analysis of treatment responders, partial responders and nonresponders originating from study BREEZE-AD7. J. Eur. Acad. Dermatol. Venereol.37(5), 1036–1045 (2023).
   PubMed Web of Science ®Google Scholar
• Bieber T , ReichK , PaulCet al. BREEZE-AD4 study group. Efficacy and safety of baricitinib in combination with topical corticosteroids in patients with moderate-to-severe atopic dermatitis with inadequate response, intolerance or contraindication to ciclosporin: results from a randomized, placebo-controlled, phase III clinical trial (BREEZE-AD4). Br. J. Dermatol.187(3), 338–352 (2022).
   PubMed Web of Science ®Google Scholar
• Taylor PC , BieberT , AltenRet al. Baricitinib safety for events of special interest in populations at risk: analysis from randomised trial data across rheumatologic and dermatologic indications. Adv. Ther.40(4), 1867–1883 (2023).
   PubMedGoogle Scholar
• Bieber T , ThyssenJP , ReichKet al. Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials. J. Eur. Acad. Dermatol. Venereol.35(2), 476–485 (2021).
   PubMed Web of Science ®Google Scholar
• Simpson EL , LacourJP , SpelmanLet al. Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. Br. J. Dermatol.183(2), 242–255 (2020).
   PubMed Web of Science ®Google Scholar
• Werfel T , IrvineAD , BangertCet al. An integrated analysis of herpes virus infections from eight randomized clinical studies of baricitinib in adults with moderate-to-severe atopic dermatitis. J. Eur. Acad. Dermatol. Venereol.36(9), 1486–1496 (2022).
   PubMed Web of Science ®Google Scholar
• King B , MaariC , LainEet al. Safety analysis of baricitinib 2 mg in adult patients with atopic dermatitis: an integrated analysis from eight randomized clinical trials. Am. J. Clin. Dermatol.22(3), 395–405 (2021).
   PubMed Web of Science ®Google Scholar
• Katoh N , TakitaY , IsakaY , NishikawaA , Torisu-ItakuraH , SaekiH. Pooled safety analysis of baricitinib in adult participants with atopic dermatitis in the Japanese subpopulation from six randomized clinical trials. Dermatol. Ther. (Heidelb.)12(12), 2765–2779 (2022).
   PubMed Web of Science ®Google Scholar
• Bieber T , KatohN , SimpsonELet al. Safety of baricitinib for the treatment of atopic dermatitis over a median of 1.6 years and up to 3.9 years of treatment: an updated integrated analysis of eight clinical trials. J. Dermatolog. Treat.34(1), 2161812 (2023).
   PubMed Web of Science ®Google Scholar
• Rogner D , BiedermannT , LaufferF. Treatment of atopic dermatitis with baricitinib: first real-life experience. Acta Derm. Venereol.102, adv00677 (2022).
   PubMed Web of Science ®Google Scholar
• Uchiyama A , FujiwaraC , InoueY , MotegiSI. Real-world effectiveness and safety of baricitinib in Japanese patients with atopic dermatitis: a single-center retrospective study. J. Dermatol.49(4), 469–471 (2022).
   PubMed Web of Science ®Google Scholar
• Boesjes CM , KamphuisE , ZuithoffNPAet al. Daily practice experience of baricitinib treatment for patients with difficult-to-treat atopic dermatitis: results from the BioDay Registry. Acta Derm. Venereol.102, adv00820 (2022).
   PubMedGoogle Scholar
• Hagino T , SaekiH , FujimotoE , KandaN. Efficacy and safety of baricitinib treatment for moderate to severe atopic dermatitis in real-world practice in Japan. J. Dermatol.50(7), 869–879 (2023).
   PubMed Web of Science ®Google Scholar
• Chovatiya R , PallerAS. JAK inhibitors in the treatment of atopic dermatitis. J. Allergy Clin. Immunol.148(4), 927–940 (2021).
   PubMed Web of Science ®Google Scholar
• US FDA . FDA approves first systemic treatment for alopecia areata. www.fda.gov/news-events/press-announcements/fda-approves-first-systemic-treatment-alopecia-areata
   Google Scholar
• Rubin R . Baricitinib Is first approved COVID-19 immunomodulatory treatment. JAMA327(23), 2281 (2022).
   Web of Science ®Google Scholar
• EMA . Janus kinase inhibitors (JAKi). www.ema.europa.eu/en/medicines/human/referrals/janus-kinase-inhibitors-jaki
   Google Scholar
• Ytterberg SR , BhattDL , MikulsTRet al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N. Engl. J. Med.386(4), 316–326 (2022).
   PubMed Web of Science ®Google Scholar
• Salinas CA , LouderA , PolinskiJB023Study Consortiumet al. Evaluation of VTE, MACE, and serious infections among patients with RA treated with baricitinib compared to TNFi: a multi-database study of patients in routine care using disease registries and claims databases. Rheumatol Ther.10(1), 201–223 (2023).
   PubMed Web of Science ®Google Scholar
• Adam DN , GooderhamMJ , BeeckerJRet al. Expert consensus on the systemic treatment of atopic dermatitis in special populations. J. Eur. Acad. Dermatol. Venereol.37(6), 1135–1148 (2023).
   PubMed Web of Science ®Google Scholar
• Bieber T , KatohN , SimpsonELet al. Safety of baricitinib for the treatment of atopic dermatitis over a median of 1.6 years and up to 3.9 years of treatment: an updated integrated analysis of eight clinical trials. J. Dermatolog. Treat.34(1), 2161812 (2023).
   PubMed Web of Science ®Google Scholar